STOCK TITAN
  1. Home
  2. Sec-filings
  3. SUPN
  4. [Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity

SUPERNUS (NASDAQ: SUPN) director logs option exercise and new share grant

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. director Georges Gemayel reported a mix of equity award activity and option exercises. On February 24, 2026, 4,475 restricted stock units were disposed of back to the issuer, while a matching 4,475 shares of common stock were acquired as a grant at no cost, bringing direct holdings in common stock to 38,159 shares.

On February 23, 2026, he exercised a director stock option for 15,000 shares of common stock at an exercise price of $12.98 per share, increasing his direct common stock ownership to 33,684 shares immediately after that exercise. Footnotes state each restricted stock unit represents one share of common stock and will settle in stock upon vesting on February 19, 2026.

Positive

  • None.

Negative

  • None.

Insights

Routine director equity grant and option exercise with no open-market buying or selling.

The transactions by Georges Gemayel reflect typical board-level equity administration at SUPERNUS PHARMACEUTICALS, INC.. A director stock option for 15,000 shares was exercised at $12.98, converting options into common stock without any reported market sale.

In addition, a grant of 4,475 common shares and a corresponding disposition of restricted stock units back to the issuer were reported at zero price, consistent with equity award mechanics. Overall, these actions adjust the mix of derivative and non-derivative holdings rather than signaling directional trading, and do not materially alter the broader investment case.

Insider GEMAYEL GEORGES
Role Director
Type Security Shares Price Value
Disposition Restricted Stock Unit 4,475 $0.00 --
Grant/Award Common Stock 4,475 $0.00 --
Exercise Director Stock Option (Right to Buy) 15,000 $0.00 --
Exercise Common Stock 15,000 $12.98 $195K
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 38,159 shares (Direct); Director Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GEMAYEL GEORGES
(Last) (First) (Middle)
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/23/2026 M 15,000 A $12.98 33,684 D
Common Stock 02/24/2026 A 4,475 A $0 38,159 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) $12.98 02/23/2026 M 15,000 03/01/2017 03/01/2026 Common Stock 15,000 $0 0 D
Restricted Stock Unit (1) 02/24/2026 D 4,475 (2) (2) Common Stock 4,475 $0 0 D
Explanation of Responses:
1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.
Remarks:
/s/ Timothy C. Dec, as attorney-in-fact 02/25/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Georges Gemayel report at SUPN?

Georges Gemayel reported exercising a director stock option for 15,000 shares at $12.98 and receiving a grant of 4,475 common shares. He also recorded a corresponding 4,475-unit disposition of restricted stock units back to the issuer as part of award settlement mechanics.

Did the SUPN director buy or sell shares on the open market?

The reported SUPN transactions do not show any open-market purchases or sales. They involve an option exercise converting 15,000 options into common shares and a share grant paired with restricted stock unit disposition, all tied to equity compensation rather than market trading.

How many SUPN common shares does Georges Gemayel hold after these transactions?

After these transactions, Georges Gemayel directly holds 38,159 shares of SUPN common stock. This reflects the 15,000-share option exercise on February 23, 2026, and the 4,475-share grant on February 24, 2026, with no reported open-market sales of common stock.

What was the exercise price for the SUPN director stock option?

The director stock option was exercised for 15,000 shares of SUPN common stock at an exercise price of $12.98 per share. This transaction converted derivative holdings into directly owned common shares as part of the company’s equity compensation program for its director.

What do the SUPN restricted stock unit disclosures mean for shareholders?

Each restricted stock unit represents the right to receive one share of SUPN common stock upon vesting. The filing notes 4,475 units that will settle in common stock upon vesting on February 19, 2026, illustrating how director equity awards may convert into actual shares over time.

Were any SUPN shares disposed of by the director in this Form 4?

The Form 4 shows a disposition of 4,475 restricted stock units back to the issuer, recorded at a zero price. This disposition is paired with a 4,475-share common stock grant and reflects internal award settlement mechanics, not a sale of common shares into the market.